Autoimmune Diseases  >>  Rebif (human IFN-β-1a)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

19 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
NCT00367484 / 2004-000337-12: Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Completed
4
460
Europe
Rebif® (clone 484-39), Recombinant-human interferon beta-1a, r-hIFN Beta-1a
Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
01/06
01/06
NCT00078338: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Completed
4
764
US, Europe, RoW
Rebif®, Recombinant interferon beta-1a, Copaxone®, Glatiramer acetate
EMD Serono, Pfizer
Relapsing-remitting Multiple Sclerosis
11/06
11/06
NCT00202995: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Terminated
4
91
US
Glatiramer Acetate, Betaseron, Rebif
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
10/07
10/07
NCT00317941: Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

Completed
4
220
Europe
Betaferon/Betaseron, Rebif
Bayer
Relapsing-remitting Multiple Sclerosis
04/08
04/08
REMAIN, NCT01142466: A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

Completed
4
30
Europe
Interferon beta-1a (Rebif), Rebif
Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH
Multiple Sclerosis, Relapsing-Remitting
12/09
01/10
SEPTIME, NCT01201343: Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

Completed
4
79
Europe
Interferon beta-1a, Rebif
Merck KGaA, Darmstadt, Germany, Merck Serono S.A.S, France
Multiple Sclerosis, Relapsing, Remitting
07/10
07/10
REGARD-PGx, NCT01034579 / 2009-016087-37: The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

Completed
4
324
US
Blood sampling
EMD Serono
Relapsing Multiple Sclerosis
11/10
11/10
NCT01085318: Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Checkmark ACTRIMS 2014: MS
Jun 2014 - Jun 2014: ACTRIMS 2014: MS
Checkmark
Mar 2014 - Mar 2014: 
Checkmark AAN 2014: Multiple sclerosis
More
Completed
4
38
US
Rebif
EMD Serono
Multiple Sclerosis
02/12
03/12
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Checkmark CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Jun 2013 - Jun 2013: CMSC-ACTRIMS 2013: Multiple sclerosis (EPOC)
Checkmark EPOC
May 2013 - May 2013: EPOC
Checkmark ENS 2013: Multiple sclerosis (EPOC)
More
Completed
4
1053
US, Canada
Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia®
Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
08/12
08/12
EPOC, NCT01534182: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg

Checkmark AAN 2014: Multiple sclerosis (EPOC)
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (EPOC)
Checkmark ECTRIMS 2013: Multiple sclerosis (EPOC)
Sep 2013 - Sep 2013: ECTRIMS 2013: Multiple sclerosis (EPOC)
Completed
4
298
RoW
Fingolimod, Gilenya, Interferon beta - 1a (IFN), Rebif, Glatiramer acetate (GA), Copaxone
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
06/13
06/13
NCT00101959: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects

Withdrawn
4
0
US
Rebif
EMD Serono
Relapsing-Remitting Multiple Sclerosis
 
 
EPOC, NCT01317004 / 2010-024017-31: Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

Completed
4
61
Europe
Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia®
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
06/14
06/14
OUCH, NCT01834586: Anesthetic Topical Adhesive (Syneraâ„¢) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

Completed
4
30
US
Anesthetic Topical Adhesive Synera, Synera
Brown, Theodore R., M.D., MPH
Multiple Sclerosis
03/15
03/15
RESOunD, NCT02117050: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

Terminated
4
1
US
Rebif®, interferon-beta-1a
EMD Serono
Multiple Sclerosis
04/15
04/15
NCT02019550: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

Completed
4
97
US
Rebif Rebidose, Rebiject II
EMD Serono
Multiple Sclerosis, Relapsing-Remitting
01/16
01/16
RebiQoL, NCT01791244: A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

Completed
4
93
Europe
Rebif®
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
02/16
02/16
RELIEF, NCT02064816 / 2013-004450-21: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

Completed
4
200
Europe
Rebif®
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
04/16
04/16
PROCEED, NCT02254304 / 2014-001290-14: Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

Completed
4
106
Europe
Rebif, Interferon beta-1a
Merck KGaA, Darmstadt, Germany, Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
08/16
08/16
Frequency, NCT02234869: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

Withdrawn
4
0
US
Interferon Beta, Rebif or Betaseron/Betaferon, BIIB017 (Peginterferon beta-1a), PEGylated interferon beta-1a (IFN β-1a)
Biogen
Relapsing Multiple Sclerosis
02/17
03/18

Download Options